ArticleStem cells and cloning : advances and applications2025
Novel, Reproducible, Consortia Factors Derived from Adipose Stem Cells for Burn Wound Treatment.
Article in Stem cells and cloning : advances and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The therapeutic application of adipose-derived stem cells (ASCs) for wound healing has been reported. However, consistently controlling ASC secretory-factor levels, scaling up, and their mechanism of action have been poorly understood, which are critical steps for developing biological drugs to treat second-degree burns. Objective: Our goal is to develop a biological product, named consortia factors-δ2 (CFx-δ2), derived from cell-to-cell interactions between human immortalized ASCs using our patented technology and to evaluate the product consistency and in vitro biological effects to enhance the wound healing process. Methods: To assess product consistency, three batches of CFx-δ2 were analyzed and compared using immunomicroarray and metabolomics. The biological effects of these batches were studied using an in vitro wound healing assay and ex vivo human skin explants subjected to burn wounds. Anti-inflammatory effects were analyzed by inhibition of Nuclear Factor- κB (NF-κB) nuclear translocation in human dermal endothelial cells (HMEC-1). Finally, pro-angiogenesis was evaluated by the induction of tube-like structures and capillary networks in HMEC-1 cells promoted by CFx-δ2. Results: Our technology enabled the production of CFx-δ2 with enhanced efficiency and quality. When the three batches were compared, we found high consistency in the pattern and levels of cytokines as well as a strong correlation in the metabolite pattern. Accelerated wound healing was observed after in vitro and ex vivo wound treatment with CFx-δ2 in comparison to controls. The nuclear translocation of NF-κB, induced by Lipopolysaccharides (LPS), was 50% inhibited by CFx-δ2. Induction of more tube-like structures and networks was observed in endothelial cells treated with CFx-δ2 in comparison to controls. Discussion: These findings demonstrate that our technology is efficient to derive and scale up consistent levels of CFx-δ2 from immortalized adipose stem cells. The product accelerates wound healing by increasing fibroblast proliferation and migration, inhibiting inflammation, and promoting angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.